Cargando…

Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial

BACKGROUND: Prehypertension and hypertension are associated with cardiovascular disease, ischemic heart disease, and stroke morbidity. The purpose of this study is to evaluate the effectiveness and safety of moxibustion in patients with prehypertension or hypertension. METHODS: Forty-five subjects w...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Kyung-Min, Park, Ji-Eun, Yook, Tae-Han, Kim, Jong-Uk, Kwon, Ojin, Choi, Sun-Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309023/
https://www.ncbi.nlm.nih.gov/pubmed/30596012
http://dx.doi.org/10.1016/j.imr.2018.11.002
_version_ 1783383325807738880
author Shin, Kyung-Min
Park, Ji-Eun
Yook, Tae-Han
Kim, Jong-Uk
Kwon, Ojin
Choi, Sun-Mi
author_facet Shin, Kyung-Min
Park, Ji-Eun
Yook, Tae-Han
Kim, Jong-Uk
Kwon, Ojin
Choi, Sun-Mi
author_sort Shin, Kyung-Min
collection PubMed
description BACKGROUND: Prehypertension and hypertension are associated with cardiovascular disease, ischemic heart disease, and stroke morbidity. The purpose of this study is to evaluate the effectiveness and safety of moxibustion in patients with prehypertension or hypertension. METHODS: Forty-five subjects with prehypertension or stage I hypertension were randomized into three groups: moxibustion treatment group A (2 sessions/week for 4 weeks), moxibustion treatment group B (3 sessions/week for 4 weeks), and control group (nontreated group). The primary outcome measure was the change in blood pressure after 4 weeks of treatment. Safety was assessed at every visit. RESULTS: There were no significant differences in systolic blood pressure (SBP) or diastolic blood pressure (DBP) among three groups after 4 weeks of treatment (p = 0.4798 and p = 0.3252, respectively). In treatment group B, there was a significant decrease in SBP and DBP from baseline to 4 weeks of treatment (mean difference (MD) −9.55; p = 0.0225, MD −7.55; p = 0.0098, respectively). There were no significant differences among groups in secondary outcome measures after 4 weeks of treatment. Six adverse events (AEs) in the treatment group A and 12 AEs in the treatment group B occurred related to the moxibustion treatment. CONCLUSION: In conclusion, the results of this study show that moxibustion (3 sessions/week for 4 weeks) might lower blood pressure in patients with prehypertension or stage I hypertension and treatment frequency might affect effectiveness of moxibustion in BP regulation. Further randomized controlled trials with a large sample size on prehypertension and hypertension should be conducted. TRIAL REGISTRATION: This study was registered with the ‘Clinical Research Information Service (CRIS)’, Republic of Korea (KCT0000469), and the protocol for this study was presented orally at the 15th International Council of Medical Acupuncture and Related Techniques (ICMART) in Athens, 25–27 May 2012.
format Online
Article
Text
id pubmed-6309023
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63090232018-12-28 Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial Shin, Kyung-Min Park, Ji-Eun Yook, Tae-Han Kim, Jong-Uk Kwon, Ojin Choi, Sun-Mi Integr Med Res Original Article BACKGROUND: Prehypertension and hypertension are associated with cardiovascular disease, ischemic heart disease, and stroke morbidity. The purpose of this study is to evaluate the effectiveness and safety of moxibustion in patients with prehypertension or hypertension. METHODS: Forty-five subjects with prehypertension or stage I hypertension were randomized into three groups: moxibustion treatment group A (2 sessions/week for 4 weeks), moxibustion treatment group B (3 sessions/week for 4 weeks), and control group (nontreated group). The primary outcome measure was the change in blood pressure after 4 weeks of treatment. Safety was assessed at every visit. RESULTS: There were no significant differences in systolic blood pressure (SBP) or diastolic blood pressure (DBP) among three groups after 4 weeks of treatment (p = 0.4798 and p = 0.3252, respectively). In treatment group B, there was a significant decrease in SBP and DBP from baseline to 4 weeks of treatment (mean difference (MD) −9.55; p = 0.0225, MD −7.55; p = 0.0098, respectively). There were no significant differences among groups in secondary outcome measures after 4 weeks of treatment. Six adverse events (AEs) in the treatment group A and 12 AEs in the treatment group B occurred related to the moxibustion treatment. CONCLUSION: In conclusion, the results of this study show that moxibustion (3 sessions/week for 4 weeks) might lower blood pressure in patients with prehypertension or stage I hypertension and treatment frequency might affect effectiveness of moxibustion in BP regulation. Further randomized controlled trials with a large sample size on prehypertension and hypertension should be conducted. TRIAL REGISTRATION: This study was registered with the ‘Clinical Research Information Service (CRIS)’, Republic of Korea (KCT0000469), and the protocol for this study was presented orally at the 15th International Council of Medical Acupuncture and Related Techniques (ICMART) in Athens, 25–27 May 2012. Elsevier 2019-03 2018-11-24 /pmc/articles/PMC6309023/ /pubmed/30596012 http://dx.doi.org/10.1016/j.imr.2018.11.002 Text en © 2018 Korea Institute of Oriental Medicine. Published by Elsevier. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Shin, Kyung-Min
Park, Ji-Eun
Yook, Tae-Han
Kim, Jong-Uk
Kwon, Ojin
Choi, Sun-Mi
Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial
title Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial
title_full Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial
title_fullStr Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial
title_full_unstemmed Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial
title_short Moxibustion for prehypertension and stage I hypertension: a pilot randomized controlled trial
title_sort moxibustion for prehypertension and stage i hypertension: a pilot randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309023/
https://www.ncbi.nlm.nih.gov/pubmed/30596012
http://dx.doi.org/10.1016/j.imr.2018.11.002
work_keys_str_mv AT shinkyungmin moxibustionforprehypertensionandstageihypertensionapilotrandomizedcontrolledtrial
AT parkjieun moxibustionforprehypertensionandstageihypertensionapilotrandomizedcontrolledtrial
AT yooktaehan moxibustionforprehypertensionandstageihypertensionapilotrandomizedcontrolledtrial
AT kimjonguk moxibustionforprehypertensionandstageihypertensionapilotrandomizedcontrolledtrial
AT kwonojin moxibustionforprehypertensionandstageihypertensionapilotrandomizedcontrolledtrial
AT choisunmi moxibustionforprehypertensionandstageihypertensionapilotrandomizedcontrolledtrial